非霍奇金淋巴瘤MDR1基因C3435T位点多态性的临床研究

The impact of MDR1 gene C3435T polymorphisms on clinicopathological characteristics and treatment response of cases with non-Hodgkin lymphoma

目的探讨MDR1基因C3435T位点多态性与非霍奇金淋巴瘤(NHL)临床特征、病理类型、化疗疗效及血液毒性的关系。方法收集67例NHL患者外周静脉血及相关的临床资料;应用聚合酶链反应-限制性片段长度多态性分析技术检测患者MDR1基因C3435T位点基因型,采用卡方检验,评估MDR1基因C3435T位点多态性与NHL患者临床病理特征、化疗疗效及化疗后血液毒性的关系。结果(1)MDR1基因C3435T位点的CC/CT基因型和TT基因型在年龄、病理细胞来源、临床分期、体能状况、结外器官受累数目、化疗前乳酸脱氢酶水平方面的差异均无统计学意义(P>0.05)。(2)CC/CT基因型和TT基因型患者的缓解率差异无统计学意义(P>0.05)。(3)TT基因型患者4级白细胞减少的发生率显著高于CC/CT基因型(P<0.05),但两组患者血红蛋白减少和血小板减少的发生率差异无统计学意义(P>0.05)。结论MDR1基因C3435T位点多态性与NHL化疗后的缓解率无关,与NHL的临床病理特征亦无关,TT基因型患者化疗后出现4级白细胞减少的风险增大。

Objective To analyze the relationship between MDR1 Gene C3435T Polymorphisms and the clinical characteristics,treatment response,and hematological toxicity of cases with non-Hodgkin lymphoma（NHL）.Methods The study was carried out on blood samples from 67 patients with Non-Hodgkin Lymphoma,and MDR1 genotype was detected by analysis of DNA restriction fragment length polymorphism（PCR-RFLP）.The significance of differences（disease or treatment effect） between the varied groups was evaluated by chi-square test with SPSS 13.0.Results There were not significant differences in response rate,age,pathological type,disease stage,PS score,extranodal involvement,LDH level between groups of CC/CT genotype and the TT genotype（P〉0.05）.Patients with TT genotype have a higher rate of grade 4 leucocyte toxicity than those with CC/CT genotype（P〈0.05）,but the hemoglobin and platelet toxicity showed no significant differences between these 2 groups（P〉0.05）.Conclusion The MDR1 C3435T polymorphism is not related to the clinicopathological characteristics and the response rates of patients with NHL,but patients with TT genotype is easier to suffer grade 4 leucocyte toxicity.